tbuckley/cabot-search huggingface dataset:
P2.15-13 Implementation of a Democratized Approach to Multi-Omic Molecular Profiling Via the LungMATCH Program.
Authors: J. King, R.J. Bender, A. Ciupek, A. Jaitly, T. Perloff, K. Mason, S. Madhavan, E. Petricoin
Journal: Journal of Thoracic Oncology (2018)
A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht)
Authors: M. Salati, F. Caputo, A. Spallanzani, M. Rimini, F. Gelsomino, K. Andrikou, S. Cascinu
Journal: Annals of Oncology (2018)
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Authors: F. Cappuzzo, M. McCleod, M. Hussein, A. Morabito, A. Rittmeyer, H.J. Conter, H.-G. Kopp, D. Daniel, S. McCune, T. Mekhail, A. Zer, N. Reinmuth, A. Sadiq, V. Archer, T. Ochi Lohmann, L. Wang, M. Kowanetz, W. Lin, A. Sandler, H. West
Journal: Annals of Oncology (2018)
MA03.02 Prospective Evaluation of the Clinical Utility of the International Lung Screen Trial Lung Nodule Management Protocol
Authors: S. Lam, R. Myers, S. Atkar-Khattra, R. Yuan, J. Yee, J. English, K. Grant, A. Lee, A. Mcguire, A. McWilliams, F. Brims, E. Stone, V. Chin, L. Chantrill, M. Connellan, M. Plitt, H. Marshall, I. Yang, R. Bowman, K. Fong, J. Mayo
Journal: Journal of Thoracic Oncology (2018)
Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension
Authors: Shalini M Krishnan, Yeong H Ling, Brooke M Huuskes, Dorota M Ferens, Narbada Saini, Christopher T Chan, Henry Diep, Michelle M Kett, Chrishan S Samuel, Barbara K Kemp-Harper, Avril A B Robertson, Matthew A Cooper, Karlheinz Peter, Eicke Latz, Ashley S Mansell, Christopher G Sobey, Grant R Drummond, Antony Vinh
Journal: Cardiovascular Research (2018)

Renal inflammation, leading to fibrosis and impaired function is a major contributor to the development of hypertension. The NLRP3 inflammasome mediates inflammation in several chronic diseases by processing the cytokines pro-interleukin (IL)-1β and pro-IL-18. In this study, we investigated whether MCC950, a recently-identified inhibitor of NLRP3 activity, reduces blood pressure (BP), renal inflammation, fibrosis and dysfunction in mice with established hypertension. C57BL6/J mice were made hypertensive by uninephrectomy and treatment with deoxycorticosterone acetate (2.4 mg/day, s.c.) and 0.9% NaCl in the drinking water (1K/DOCA/salt). Normotensive controls were uninephrectomized and received normal drinking water. Ten days later, mice were treated with MCC950 (10 mg/kg/day, s.c.) or vehicle (saline, s.c.) for up to 25 days. BP was monitored by tail-cuff or radiotelemetry; renal function by biochemical analysis of 24-h urine collections; and kidney inflammation/pathology was assessed by real-time PCR for inflammatory gene expression, flow cytometry for leucocyte influx, and Picrosirius red histology for collagen. Over the 10 days post-surgery, 1K/DOCA/salt-treated mice became hypertensive, developed impaired renal function, and displayed elevated renal levels of inflammatory markers, collagen and immune cells. MCC950 treatment from day 10 attenuated 1K/DOCA/salt-induced increases in renal expression of inflammasome subunits (NLRP3, ASC, pro-caspase-1) and inflammatory/injury markers (pro-IL-18, pro-IL-1β, IL-17A, TNF-α, osteopontin, ICAM-1, VCAM-1, CCL2, vimentin), each by 25–40%. MCC950 reduced interstitial collagen and accumulation of certain leucocyte subsets in kidneys of 1K/DOCA/salt-treated mice, including CD206+ (M2-like) macrophages and interferon-gamma-producing T cells. Finally, MCC950 partially reversed 1K/DOCA/salt-induced elevations in BP, urine output, osmolality, [Na+], and albuminuria (each by 20–25%). None of the above parameters were altered by MCC950 in normotensive mice. MCC950 was effective at reducing BP and limiting renal inflammation, fibrosis and dysfunction in mice with established hypertension. This study provides proof-of-concept that pharmacological inhibition of the NLRP3 inflammasome is a viable anti-hypertensive strategy.
P2.01-71 Clinical Outcome of Induction Chemoradiotherapy Followed by Surgery for the Patients with cN2 Non-Small Cell Lung Cancer
Authors: A. Miura, J. Soh, K. Araki, Y. Takahashi, E. Kurihara, Y. Ogoshi, K. Shien, H. Yamamoto, S. Sugimoto, M. Yamane, K. Kiura, S. Kanazawa, S. Toyooka
Journal: Journal of Thoracic Oncology (2018)
Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Authors: T.H. Carr, C. Adelman, A. Barnicle, I. Kozarewa, S. Luke, Z. Lai, S. Menon, S. Hollis, B. Dougherty, E.A. Harrington, J.C. Barrett, C. Goessl, F. Saad, N. Sala, N.W. Clarke, D. Hodgson
Journal: Annals of Oncology (2018)
Folfiri-aflibercept vs folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice
Authors: A. Ottaiano, M. Capozzi, C. De Divitiis, A. Cassata, A. De Stefano, S. Tafuto, A. Avallone, G. Nasti
Journal: Annals of Oncology (2018)
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS
Authors: Howard Trachtman, Peter Nelson, Sharon Adler, Kirk N. Campbell, Abanti Chaudhuri, Vimal Kumar Derebail, Giovanni Gambaro, Loreto Gesualdo, Debbie S. Gipson, Jonathan Hogan, Kenneth Lieberman, Brad Marder, Kevin Edward Meyers, Esmat Mustafa, Jai Radhakrishnan, Tarak Srivastava, Miganush Stepanians, Vladimír Tesar, Olga Zhdanova, Radko Komers
Journal: Journal of the American Society of Nephrology (2018)

Background We evaluated and compared the effects of sparsentan, a dual endothelin type A (ET A ) and angiotensin II type 1 receptor antagonist, with those of the angiotensin II type 1 receptor antagonist irbesartan in patients with primary FSGS. Methods In this phase 2, randomized, double-blind, active-control Efficacy and Safety of Sparsentan (RE-021), a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Randomized, Double-blind, Active-Control, Dose-Escalation Study (DUET), patients aged 8–75 years with biopsy-proven FSGS, eGFR&gt;30 ml/min per 1.73 m 2 , and urinary protein-to-creatinine ratio (UP/C) ≥1.0 g/g received sparsentan (200, 400, or 800 mg/d) or irbesartan (300 mg/d) for 8 weeks, followed by open-label sparsentan only. End points at week 8 were reduction from baseline in UP/C (primary) and proportion of patients achieving FSGS partial remission end point (FPRE) (UP/C: ≤1.5 g/g and &gt;40% reduction [secondary]). Results Of 109 patients randomized, 96 received study drugs and had baseline and week 8 UP/C measurements. Sparsentan-treated patients had greater reductions in UP/C than irbesartan-treated patients did when all doses (45% versus 19%; P =0.006) or the 400 and 800 mg doses (47% versus 19%; P =0.01) were pooled for analysis. The FSGS partial remission end point was achieved in 28% of sparsentan-treated and 9% of irbesartan-treated patients ( P =0.04). After 8 weeks of treatment, BP was reduced with sparsentan but not irbesartan, and eGFR was stable with both treatments. Overall, the incidence of adverse events was similar between groups. Hypotension and edema were more common among sparsentan-treated patients but did not result in study withdrawals. Conclusions Patients with FSGS achieved significantly greater reductions in proteinuria after 8 weeks of sparsentan versus irbesartan. Sparsentan was safe and well tolerated.
Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
Authors: S. Pernas, P. Villagrasa, A. Vivancos, M. Scaltriti, J. Rodon, O. Burgues, P.G. Nuciforo, J. Canes, M. Dueñas, M. Vidal, A. Lluch, A. Perelló, A. Llombart, J. Dorca, Á Montaño, M. Oliveira, G. Ribas, I. Rapado, A. Prat, E.M. Ciruelos
Journal: Annals of Oncology (2018)
P1.03-28 Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with Nsclc in Chinese Patients
Authors: J. Lai, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Huang, Y. Zhu, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Authors: M. Javle, R.K. Kelley, S. Roychowdhury, K.H. Weiss, G.K. Abou-Alfa, T. Macarulla, S. Sadeghi, D. Waldschmidt, A.X. Zhu, L. Goyal, M. Borad, W.P. Yong, I. Borbath, A. El-Khoueiry, P. Philip, S. Moran, Y. Ye, M. Ising, N. Lewis, T. Bekaii-Saab
Journal: Annals of Oncology (2018)
Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC)
Authors: S. Chowdhury, R. McDermott, J.M. Piulats, J.D. Shapiro, I. Mejlholm, D. Morris, P. Ostler, A. Hussain, I. Dumbadze, E.R. Goldfischer, E. Pintus, A. Benjelloun, M.E. Gross, S. Tejwani, G. Chatta, A. Font, A. Loehr, A.D. Simmons, S.P. Watkins, W. Abida
Journal: Annals of Oncology (2018)
MS29.03 Polygenic Risk Score for Risk Assessment
Authors: R. Hung, Y. Brhane, N. Chatterjie, D. Christiani, N. Caporaso, M. Landi, L. Le Marchand, G. Liu, S. Lam, J. Field, P. Brennan, C. Amos
Journal: Journal of Thoracic Oncology (2018)
SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component
Authors: S. Mukherjee, P. Virdee, R. Shaw, J. Bridgewater, G. Radhakrishna, S. Falk, M. Scott-Brown, V.Y. Strauss, C. Brooks, R. Gillmore, N. Patel, B. Tranter, P. Parsons, D. Sebag-Montefiore, M. Hawkins, P.G. Corrie, T.S. Maughan
Journal: Annals of Oncology (2018)
P2.13-45 SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC
Authors: L. Sequist, P. Jänne, F. Shepherd, R. Huber, J. Gray, E. Felip, M. Pérol, F. Hirsch, D. Tan, K. Caliri, S. Ghassemifar, B. Wang, W. Kamoun, S. Santillana, V. Askoxylakis, J. Pipas
Journal: Journal of Thoracic Oncology (2018)
Abstract 12591: Preservation of Cardiac Structure and Function Compared to Brain in a Rat Hemorrhagic Shock Model
Authors: Wangde Dai, Robert A Kloner
Journal: Circulation (2016)

Background: Hemorrhagic shock (HS) and resuscitation were hypothesized to induce myocardial injury and/or stunned myocardium. In this study we assessed cardiac function during HS and resuscitation in rats. Methods: Pressure-controlled HS was induced by blood shedding (withdrawal at 0.5 ml/min) in rats (n=5). Mean arterial blood pressure (MBP) was maintained at 29 ± 1 mmHg for 2 hours, followed by resuscitation with the shed blood. At 3 hours after resuscitation, saline was infused at 0.5 ml/min (2.5 ml) to assess cardiac and vascular reactivity. Cardiac function was continuously monitored by transthoracic echocardiogram during the procedure. Brain, heart, liver and kidney were sliced and stained with triphenyltetrazolium chloride for necrosis assessment. Results: No rat died during the procedure. Heart rate, MBP, diastolic and systolic left ventricular (LV) diameter, and LV fractional shortening (LVFS) were reported at 6 time points in the table: 1) baseline prior to HS; 2) beginning of HS; 3) end of the HS; 4) post-resuscitation peak MBP; 5) end of 3 hours of post-resuscitation; 6) 5 minutes after saline infusion at 0.5 ml/min. Heart rate significantly decreased during blood shedding (p &lt; 0.05), then significantly increased during HS (p &lt; 0.05). MBP significantly fell during HS (P &lt; 0.05) and then recovered to baseline level after reinfusion of shed blood; it significantly dropped (compared to baseline) at 3 hours after resuscitation (p &lt; 0.05). Saline infusion rapidly recovered MBP, LV diastolic diameter and LVFS to baseline level, which suggested that cardiac and vascular reactivity to fluid resuscitation were preserved during HS and post-resuscitation. LVFS remained preserved throughout the study; shock did not cause stunned myocardium. There were infarcts in 5 brains; no necrosis was detected in hearts, kidneys or livers. Conclusions: Cardiac function was preserved during HS and resuscitation with no evidence of stunning or infarction, while strokes were common.
Initial treatment and survival in a national unselected Danish cohort of 4161 patients with pancreatic cancer
Authors: L.S. Rasmussen, B. Vittrup, M. Ladekarl, P. Pfeiffer, M.K. Yilmaz, L.Ø Poulsen, K. Østerlind, H. Skuladottir, C.P. Hansen, M.B. Mortensen, F.V. Mortensen, M. Sall, U.G. Falkmer, C. Fristrup
Journal: Annals of Oncology (2018)
PEGylation Regulates Self‐Assembled Small‐Molecule Dye–Based Probes from Single Molecule to Nanoparticle Size for Multifunctional NIR‐II Bioimaging
Authors: Feng Ding, Chonglu Li, Yuling Xu, Jiaxin Li, Haibing Li, Guangfu Yang, Yao Sun
Journal: Advanced Healthcare Materials (2018)

Abstract To date, small‐molecule dye–based probes have been at the forefront of research in biomedical imaging, especially in the second near‐infrared (NIR‐II) window (1.0–1.7 µm). However, how to precisely regulate the synthesized size of NIR‐II organic dye–based probes remains challenging. Moreover, systematic studies on whether the size of NIR‐II probes affects optical/pharmacokinetic properties are still rare. Here, an ingenious PEGylation strategy is developed to regulate the self‐assembly size of organic dye–based (CH1055 scaffold) NIR‐II probes (SCH1–SCH4) from nanoparticles to the single molecule, and the relationship between their size and chemical/physical properties is thoroughly investigated. Based on their own merits, nanoprobe SCH1 (≈170 nm), with outstanding fluorescent brightness (quantum yield ≈0.14%), performs accurate tracing of the lymphatic system as well as identification of vessel networks in mice brains with excellent signal‐to‐background ratio images. Meanwhile, rapidly excreted SCH4, showing fast and high passive liver tumor uptake and promising tumor/normal tissue ratios (&gt;7), is capable of facilitating precise image‐guided tumor surgery, and also demonstrates the first example of the assessment of liver fibrosis in the NIR‐II window.
A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome
Authors: Hao Guo, Changrim Lee, Mihir Shah, Srikanth R. Janga, Maria C. Edman, Wannita Klinngam, Sarah F. Hamm-Alvarez, J. Andrew MacKay
Journal: Journal of Controlled Release (2018)
P1.13-07 Epithelial-Mesenchymal Transition Induced the Acquired Resistance to ALK Inhibitor Brigatinib in Lung Cancer Cells Harboring with ALK Fusions
Authors: K. Tanimura, T. Yamada, N. Okura, J. Uchino, K. Takayama
Journal: Journal of Thoracic Oncology (2018)
Abstract P030: Long-term Pharmacotherapy for Elevated Low Density Lipoprotein Levels in Children: A Retrospective Analysis
Authors: Collin C John, Michael Regier, Christa Lilly, Shahenda Aly
Journal: Circulation (2016)

Background: There is limited research detailing LDL trends over the long term in children on various lipid lowering medications. Objectives: This study sought to assess factors associated with stability of LDL levels in children on long-term pharmacotherapy and their ability to reach the current recommended LDL goal of 130 mg/dL or less while on pharmacotherapy. Methods: Medical records of children seen in a university pediatric cholesterol clinic between 1998 and 2012 who were treated with a statin, ezetimibe, or both were reviewed. Aggregate data were obtained to determine the number of children who were able to reach an LDL level of 130 mg/dL or less while on pharmacotherapy. Kaplan-Meier curve and proportional hazard regression analysis were used to examine the propensity for LDL levels to stabilize over time while on pharmacotherapy as well as factors affecting this propensity. Results: 76 patients who contributed 864 total visits met inclusion criteria. 56 of 76 patients developed a stable LDL with median time to stability of 28 months on pharmacotherapy. Younger age of first visit was associated with development of LDL stability (9.8 years for stable LDL vs. 13.3 years for nonstable LDL; p= 0.004). Titration to higher statin doses and/or higher potency statins was also associated with higher propensity for LDL stabilization. There was no significant difference between patients who were taking a statin, ezetimibe, or both in terms of their propensity to stabilize even when stratifying for presence of probable familial hypercholesterolemia (p=0.579). 36 of 76 patients were able to reach an LDL of 130 mg/dL or less, with only 11 of 38 patients with probable familial hypercholesterolemia (&gt;190 mg/dL baseline LDL) reaching this goal. Conclusion: A majority of children in a university pediatric cholesterol clinic were able to reach a stable LDL level on pharmacotherapy after a median 28 month interval. On the other hand, the majority of children had difficulty reaching the current recommended goal LDL of 130 mg/dL or less, even after aggressive titration of medication. This was specifically true for those with probable familial hypercholesterolemia. Further research is needed to assess the utility of goal-directed therapy in children with regards to cardiovascular outcomes.
Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC)
Authors: A. Sobrero, H.-J. Lenz, C. Eng, W. Scheithauer, G. Middleton, W. Chen, R. Esser, J. Nippgen, H. Burris
Journal: Annals of Oncology (2018)
Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy
Authors: M. Pracht, E. Chajon, T. de Baere, F. Nguyen, J.-P. Bronowicki, V. Vendrely, A.-S. Baumann, V. Croisé-Laurent, E. Rio, Y. Rolland, S. Le Sourd, P. Gustin, C. Perret, F. Mornex, D. Peiffert, P. Merle, E. Deutsch
Journal: Annals of Oncology (2018)
IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC
Authors: M.A. Socinski, A. Rittmeyer, D. Shapovalov, F. Orlandi, M. McCleod, R.A. Soo, R. Palmero, T. Kozuki, M.R. Migliorino, K.D. Koynov, H. Berard, B.G.M. Hughes, W. Yu, V. Graupner, S.W. Sun, M. Kowanetz, T. Hoang, W. Lin, R.M. Jotte
Journal: Annals of Oncology (2018)
Abstract 12843: Impact of Age on Optimal Cardiopulmonary Resuscitation Duration to Achieve Favorable Neurological Outcomes After Out-of-hospital Cardiac Arrest: Evidence From a Large-scale Registry in Japan
Authors: Akira Funada, Yoshikazu Goto, Tetsuo Maeda, Hayato Tada, Ryota Teramoto, Masaya Shimojima, Kenshi Hayashi, Masakazu Yamagishi
Journal: Circulation (2016)

Introduction: The optimal duration of cardiopulmonary resuscitation (CPR) for patients with out-of-hospital cardiac arrest (OHCA) before cessation of CPR is unclear and could differ according to age. Hypothesis: We determined the relationship between the duration of prehospital CPR performed by emergency medical service (EMS) personnel and survival with favorable neurological outcome (cerebral performance category scale, category 1 or 2; CPC 1-2) after OHCA by age. Methods: We analyzed the records of 17,238 OHCA patients (age ≥18 years) who achieved return of spontaneous circulation (ROSC) before arrival at the hospital. Data were obtained from a prospectively recorded Japanese national Utstein-style database for 2 years (2011-2012). The time from initiation of CPR by EMS personnel to prehospital ROSC (CPR duration) was calculated. The primary end point was 1-month CPC 1-2. Results: The rate of 1-month CPC 1-2 was 21.9% (3771 of 17238) for whole OHCA. The CPR duration was independently associated with a decreased rate of 1-month CPC 1-2 (adjusted odds ratio 0.94; 95% confidence interval 0.94-0.95). The CPR duration at which the probability of 1-month CPC 1-2 decreased to &lt;1% was 24 min for whole OHCA. The minimum CPR duration to achieve a cumulative proportion &gt;99% for 1-month CPC 1-2 was 35 min for whole OHCA. When sorted by age, the rates of 1-month CPC 1-2 were 36.3% (1822 of 5018), 25.0% (926 of 3697), 14.2% (688 of 4847), 9.7% (314 of 3243), and 4.8% (21 of 433), for 18-64, 65-74, 75-84, 85-94, and ≥95 years, respectively. The CPR duration at which the probability of 1-month CPC 1-2 decreased to &lt;1% were 28, 24, 22, 21, and 19 min, for 18-64, 65-74, 75-84, 85-94, and ≥95 years, respectively. The minimum CPR duration to achieve a cumulative proportion &gt;99% for 1-month CPC 1-2 were 34, 34, 35, 39, and 36 min for 18-64, 65-74, 75-84, 85-94, and ≥95 years, respectively. Conclusions: These results demonstrate that elderly OHCA patients had worse outcome. The more elderly the OHCA patients were, the earlier the probability of 1-month CPC 1-2 decreased to &lt;1%; however, to achieve a cumulative proportion of &gt;99% for 1-month CPC 1-2, a longer CPR duration was required. When considering cessation of CPR, the difference of optimal CPR duration by age should be taken into consideration.
Left ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance
Authors: J.H. Yeo, H. Ahn, I. Park, Y.S. Kim, S.J. Sym, E.K. Cho, D.B. Shin
Journal: Annals of Oncology (2018)
Post hoc analysis of the effect of baseline characteristics on treatment duration in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel in the compassionate use (CUP)/expanded access programs (EAP) and CAPRISTANA registry
Authors: Z. Malik, A. Pichler, G. Di Lorenzo, U. De Giorgi, S. Hitier, E. Ecstein-Fraisse, A. Ozatilgan, J. Carles
Journal: Annals of Oncology (2018)
OA11.04 A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma
Authors: T. Sakane, H. Haneda, K. Okuda, K. Yokota, T. Tatematsu, R. Oda, T. Watanabe, Y. Saito, T. Yamada, R. Nakanishi
Journal: Journal of Thoracic Oncology (2018)
Clinical and psychometric validation of the BreSAS questionnaire for symptom assessment among breast cancer survivors
Authors: R. Giusti, E. Scarpi, K. Cannita, R.R. Silva, M. Filetti, M. Mazzotta, R. Rossi, V. Cocciolone, T. Sidoni, M. Tudini, C. Ficorella, A. Botticelli, P. Marchetti, G. Porzio, L. Verna
Journal: Annals of Oncology (2018)
P2.06-37 Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma
Authors: T. Watanabe, K. Okuda, S. Moriyama, H. Haneda, K. Yokota, T. Tatematsu, T. Sakane, R. Oda, R. Nakanishi
Journal: Journal of Thoracic Oncology (2018)
P2.16-07 Impact of de Novo T790M on Outcome for Resected NSCLC from EGFR Mutant Cohort of Japan Molecular Epidemiology (JME) Study
Authors: Y. Matsumoto, T. Kawaguchi, K. Sawa, S. Isa, M. Ando, A. Tamiya, A. Kubo, H. Saka, A. Matsumura, Y. Koh
Journal: Journal of Thoracic Oncology (2018)
MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)
Authors: V. Rusch, J. Chaft, B. Johnson, I. Wistuba, M. Kris, J. Lee, P. Bunn, D. Kwiatkowski, K. Reckamp, D. Finley, E. Haura, S. Waqar, R. Doebele, E. Garon, J. Blasberg, A. Nicholas, K. Schulze, S. Phan, M. Gandhi, D. Carbone
Journal: Journal of Thoracic Oncology (2018)
Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors
Authors: M.R. Middleton, M. Wermke, E. Calvo, E. Chartash, H. Zhou, X. Zhao, M. Niewel, K. Dobrenkov, V. Moreno
Journal: Annals of Oncology (2018)